McKesson (MCK) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 7, 2024, might help the stock move higher if these key numbers are better than expectati ...

The most recent trading session ended with McKesson (MCK) standing at $600.16, reflecting a +0.74% shift from the previouse trading day's closing. This change lagged the S&P 500's 1.11% gain on the day. At the same time, the Dow added 1.64%, and the tech-heavy Nasdaq gained 1.03%.The prescription drug distributor's shares have seen an increase of 0.43% over the last month, surpassing the Medical sector's loss of 0.54% and the S&P 500's loss of 1.16%.Analysts and investors alike will be keeping a close eye o ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this prescription drug distributor have returned -1.6% over the past month versus the Zacks S&P 500 composite's -0.3% change. The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has lost 1.1% over this period. Now the key question is: Where could the stock be headed in the near term?Whi ...

McKesson (MCK) is witnessing strong momentum, with its shares having rallied 26.1% year to date against 1.5% decline of the industry. The S&P 500 composite has risen 16.9% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments — Distribution Sol ...

McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a solid fourth-quarter fiscal 2024 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.Over the past year, this Zacks Rank #3 (Hold) stock has rallied 41.4%.The renowned health care services and information technology company has a market capitalization of ...

In the latest trading session, McKesson (MCK) closed at $575.23, marking a -1.98% move from the previous day. This change lagged the S&P 500's daily loss of 0.88%. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 1.95%.Shares of the prescription drug distributor witnessed a gain of 0.35% over the previous month, beating the performance of the Medical sector with its loss of 1.09% and underperforming the S&P 500's gain of 5.11%.The investment community will be closely mo ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned +7.3%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has gained 1.2%. The key question now is: What could be the stock's future direction?Althou ...

McKesson (MCK) closed the most recent trading day at $599.56, moving -0.8% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.49%.The prescription drug distributor's shares have seen an increase of 10.04% over the last month, surpassing the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%.Analysts and investors alike will be keeping a close eye on the performa ...

Shares of McKesson Corporation (MCK) scaled a new 52-week high of $605.33 on Jun 20, 2024, before closing the session slightly lower at $603.24.Over the past year, this Zacks Rank #3 (Hold) stock has gained 44.2% compared with 0.9% growth of the industry and the 24.8% rise of the S&P 500 Composite.Over the past five years, the company registered earnings growth of 14.7% compared with the industry’s 12.9% rise. The company’s long-term expected growth rate of 13.6% compares with the industry’s growth projecti ...

In the latest market close, McKesson (MCK) reached $603.24, with a +0.05% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.77%, and the Nasdaq, a tech-heavy index, lost 0.79%.Coming into today, shares of the prescription drug distributor had gained 8.17% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%.The upcoming earnings release of McKesson will be of great interest to investors. I ...